Lupin Recalls Morphine Sulfate Tablets for Impurity Specification Failures
Lupin Pharmaceuticals is recalling specific lots of Morphine Sulfate Extended-Release Tablets because they failed impurity and degradation specifications.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The FDA classified this as a Class III recall, which indicates a remote possibility of adverse health consequences. The hazard involves failed impurity specifications without reported injuries or illnesses, fitting the criteria for a moderate severity score.
Plain-English summary
Lupin Pharmaceuticals, Inc. is recalling 324 bottles of Morphine Sulfate Extended-Release Tablets, 200 mg. The affected product was manufactured by Novel Laboratories, Inc. and distributed to five wholesalers and one supermarket chain, which may have further distributed the product throughout the United States.
The recall was initiated because the product failed impurities and degradation specifications. The specific lots involved are S700224 (expiration date April 30, 2019) and S800469 (expiration date March 31, 2020).
Consumers and healthcare providers should check their inventory for these specific lot numbers and expiration dates. If the product is found, it should be returned to the pharmacy or point of purchase for disposal or replacement in accordance with the recall instructions.
The recalled product
- Product
- MORPHINE SULFATE (MORPHINE SULFATE)
- Brand
- MORPHINE SULFATE
- Manufacturer
- LUPIN SOMERSET
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 324
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot#: S700224 Exp. Apr 30 2019
- S800469 Exp. Mar 31 2020
UPCs (4)
- 0343386542017
- 0343386543014
- 0343386540013
- 0343386541010
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 5 recalled by LUPIN SOMERSET under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 5 products in this recall →Related recalls
Same brand · MORPHINE SULFATE
- CriticalFresenius Kabi Recalls Morphine Syringes Due to Labeling Error
FDA (Drugs) · 2026-08-26
- ModerateMorphine sulfate oral solution recalled over a carton size mismatch
FDA (Drugs) · 2025-12-17
- HighMorphine Sulfate Tablets Recalled Over Failed Dissolution Specifications
FDA (Drugs) · 2025-03-12
- SevereMorphine Sulfate Injection Recalled Due to Defective Vials
FDA (Drugs) · 2021-10-06
- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets Due to Impurity Failures
FDA (Drugs) · 2019-05-01
Same manufacturer · LUPIN SOMERSET
See all →- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets for Impurity Failures
FDA (Drugs) · 2019-05-01
- LowLupin Recalls Morphine Sulfate Extended-Release Tablets Due to Impurity Failures
FDA (Drugs) · 2019-05-01
- ModerateLupin Recalls Morphine Sulfate Extended-Release Tablets for Impurity Failures
FDA (Drugs) · 2019-05-01
- ModerateGavilyte-N Recalled for Incorrect Flavor Labeling on Orange and Cherry Packets
FDA (Drugs) · 2019-04-17
- ModerateLupin Recalls Fluocinolone Acetonide Topical Solution Due to Impurities
FDA (Drugs) · 2019-01-30
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17